Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 1
2012 1
2013 6
2014 5
2015 1
2016 1
2017 2
2018 1
2021 1
2022 1
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean seo young kwon[Author] (88 results)?
A phase 4 randomized active-controlled clinical study to compare the efficacy and safety of sustained-release pregabalin with immediate-release pregabalin in type 2 diabetic patients with peripheral neuropathic pain.
Joung KH, Kim TN, Ku EJ, Lee SS, Yoo WS, Park KS, Kwon SK, Ku BJ. Joung KH, et al. Among authors: kwon sk. J Diabetes Complications. 2024 Aug;38(8):108809. doi: 10.1016/j.jdiacomp.2024.108809. Epub 2024 Jul 14. J Diabetes Complications. 2024. PMID: 39018898 Clinical Trial.
Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial.
Lee YH, Kim DM, Yu JM, Choi KM, Kim SG, Park KS, Son HS, Chung CH, Ahn KJ, Lee SH, Song KH, Kwon SK, Park HK, Won KC, Jang HC; ACACIA Study Group. Lee YH, et al. Among authors: kwon sk. Diabetes Obes Metab. 2023 May;25(5):1174-1185. doi: 10.1111/dom.14959. Epub 2023 Jan 10. Diabetes Obes Metab. 2023. PMID: 36564983 Clinical Trial.
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.
Ryang S, Kim SS, Bae JC, Han JM, Kwon SK, Kim YI, Nam-Goong IS, Kim ES, Kim MK, Lee CW, Yoo S, Koh G, Kwon MJ, Park JH, Kim IJ. Ryang S, et al. Among authors: kwon sk. Diabetes Obes Metab. 2022 Sep;24(9):1800-1809. doi: 10.1111/dom.14766. Epub 2022 Jun 9. Diabetes Obes Metab. 2022. PMID: 35581902 Free PMC article. Clinical Trial.
Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines.
Yun SJ, Jeong IK, Cha JH, Lee J, Cho HC, Choi SH, Chun S, Jeon HJ, Kang HC, Kim SS, Ko SH, Koh G, Kwon SK, Lee JH, Moon MK, Noh J, Park CY, Kim S. Yun SJ, et al. Among authors: kwon sk. Diabetes Metab J. 2021 May;46(3):464-475. doi: 10.4093/dmj.2021.0088. Epub 2022 Mar 3. Diabetes Metab J. 2021. PMID: 35235742 Free PMC article.
Optimal glycemic target level for colon cancer patients with diabetes.
Lee SJ, Kim JH, Park SJ, Ock SY, Kwon SK, Choi YS, Kim BK. Lee SJ, et al. Among authors: kwon sk. Diabetes Res Clin Pract. 2017 Feb;124:66-71. doi: 10.1016/j.diabres.2016.12.009. Epub 2016 Dec 23. Diabetes Res Clin Pract. 2017. PMID: 28107755 Free article.
22 results